避孕药物醋酸烯诺孕酮的研究进展  

Review of ST-1435:First Choice Contraception for Lactating Women

作　　者：黄勇[1] 曹霖[1] 顾芝萍[1] 

机构地区：[1]中国科学院上海生命科学研究院药物研究所药理一室,上海200031

出　　处：《生殖与避孕》2003年第3期169-175,共7页Reproduction and Contraception

摘　　要：哺乳期妇女出于对婴儿安全的考虑 ,对于避孕药物的选择十分谨慎。醋酸烯诺孕酮的激素特性和药代动力学特点使其在临床试验中避孕率高 ,副作用小 ,尤其对婴儿无影响 ,其皮下埋植剂有希望成为哺乳期妇女避孕的首选药物。本文就醋酸烯诺孕酮的化学结构、激素活性、药代动力学特性、临床有效率、副作用、药物作用机制以及阴道环剂型等方面作一综述。Lactating women are very considerate in chosing contraception for the reason of infants safety. With particular hormonal activities and unique pharmacokinetics, ST 1435 has high contraception efficacy and few side effects, especially no effect on infants. ST 1435 subdermal implant is promising to be the first choice contraception for lactating women. Structure, hormonal activities, pharmacokinetics, contraception efficacy in clinical trials, side effects, mechanism of effects and vaginal ring of ST 1435 were reviewed in this paper.

关 键 词：醋酸烯诺孕酮 埋植避孕药 哺乳期妇女 

分 类 号：R979.2[医药卫生—药品]